Trends in Neoadjuvant Pembrolizumab Use in Triple-Negative Breast Cancer

This study revealed high rates of pembrolizumab utilization within a year of approval for its use in the treatment of TNBC. There were no significant differences in their use according to race and ethnicity, but patients who lived in areas of higher socioeconomic deprivation had lower rates of use.